Spots Global Cancer Trial Database for 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Official Title: 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Study ID: NCT02038738
Study Description
Brief Summary: Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ochsner Medical Center - Kenner, Kenner, Louisiana, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
